The last time I attended the Neuro-Ophthalmological Society of Australia (NOSA) meeting was in Melbourne as a first-year PhD student in 2012. I was absolutely petrified to deliver my first ever presentation to an audience composed primarily of consultant neurologists and ophthalmologists, not knowing a single person in the room. I soon realised that although it was an academically intimidating collection of people, there was a great collegial atmosphere.
I was pleased to note this friendly and collaborative environment was still present at this year’s meeting. Professor Helen Danesh-Meyer is the current president of NOSA and the first New Zealander to hold the position, so the meeting was also held in Auckland for the first time in its history. Prof Danesh-Meyer put together an exciting programme of speakers spanning a diverse range of backgrounds, including world-leading neuro-ophthalmologists from the US, UK, Australia and New Zealand, an MRI physicist, a neuropsychiatrist, research scientists, ophthalmology and neurology trainees and medical students.
The first session was opened by keynote Professor Ari Green from the University of California at San Francisco. He beautifully outlined myelin biology in multiple sclerosis (MS), pointing out that the mixture of proteins and phospholipids is one of biology’s wonders. He highlighted the importance of visual system assessment in patients with MS, particularly because close to 30% of MS patients first present with afferent visual system injury and 10–15% with efferent dysfunction. After someone has had MS for 30-plus years, the amount of axonal loss can look at least as bad as the loss seen in advanced glaucoma, but new MS therapies make a difference to how rapidly patients lose retinal nerve fibres. An interesting fact: myelination typically progresses posterior to anterior and the frontal lobe is not fully myelinated until the late teens in women and mid-20s in men!
Session two of the first day was all about idiopathic intracranial hypertension (IIH). Dr Benson Chen, a consultant neurologist and neuro-ophthalmologist at Auckland City Hospital, spoke about the condition’s expanding spectrum, ranging from IIH without papilloedema to rapidly progressing fulminant IIH. He highlighted that IIH is more than just papilloedema and headache and that the spectrum of symptoms also includes cerebrospinal fluid leak and refractory epilepsy. He also discussed glymphatic system dysfunction and its implications for the pathophysiology of IIH.










